Global BRAF Kinase Inhibitors Market 2021 Analysis May Set New Growth Story, Forecast to 2027
The global BRAF kinase inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). BRAF is a kinase enzyme that helps control cell growth and signalling. This enzyme can be found in a mutated form in some types of cancer, including melanoma and colorectal cancer. Blocking mutated BRAF kinase proteins helps to stop the cancer cells from growing. Some BRAF kinase inhibitors are used to treat cancer. The major factor that is expected to drive the global BRAF kinase inhibitors market during the forecast period includes product approvals by regulatory bodies in various regions across the globe.
Moreover, the robust pipeline of BRAF kinase inhibitor drugs
is expected to significantly drive the growth of the global BRAF kinase
inhibitors market during the forecast period. Furthermore, the global BRAF
kinase inhibitors market is anticipated to witness high growth during the
forecast period, owing to the increasing incidence and prevalence of metastatic
cancer.
To Request a Sample of our Report on Global BRAF Kinase
Inhibitors Market: https://www.omrglobal.com/request-sample/braf-kinase-inhibitors-market
The global BRAF kinase inhibitors market analysis includes some of the key
market players such as F. Hoffmann-La Roche AG, Novartis International AG, and
Pfizer, Inc., among others. To maintain a strong position in the market, these
market players are adopting various strategic moves, such as product launches,
partnerships, collaborations, and mergers and acquisitions.
Recent Development
For instance, in June 2020, BeiGene, Ltd., a commercial-stage biotechnology
company and SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical
company, announced the presentation of preclinical data and provided a program
update on their ongoing Phase 1b/2 study evaluating the combination of
BeiGene’s investigational RAF dimer inhibitor, lifirafenib, with SpringWorks’
investigational MEK inhibitor, mirdametinib, in patients with advanced or
refractory solid tumors harbouring mutations in the MAPK pathway, including
those with RAS mutations.
Market Coverage
·
The market number available for – 2020-2027
·
Base year- 2020
·
Forecast period- 2021-2027
·
Segment Covered
·
Regions Covered- Globally
·
Competitive Landscape: F.
Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc., among
others.
(Get 15% Discount on Buying this Report)
A
full Report of Global BRAF Kinase Inhibitors Market is Available
at: https://www.omrglobal.com/industry-reports/braf-kinase-inhibitors-market
Global BRAF Kinase Inhibitors Market by Segment
By Drug
• Vemurafenib
• Dabrafenib
• Lifirafenib
• Encorafenib
By Indication
• Metastatic Melanoma
• Metastatic Lung Cancer
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Global BRAF Kinase Inhibitors Market by Regional Analysis
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment